peptide,aliases,half_life_h,half_life_range_h,tmax_h,tmax_range_h,route,species,evidence_level,source_type,source,pmid,pmcid,doi,notes
Semaglutide,Ozempic;Wegovy,168,,,24-72,SC,human,A,regulatory_label,FDA label Ozempic injection (sec. 12.3),,,,Label: t1/2 about 1 week; Cmax reached 1 to 3 days post dose
Tirzepatide,Mounjaro;Zepbound,120,,,8-72,SC,human,A,regulatory_label,FDA label Mounjaro (sec. 12.3),,,,Label: t1/2 about 5 days; Tmax 8 to 72 h
Liraglutide,Victoza;Saxenda,13,,,8-12,SC,human,A,regulatory_label,FDA label Victoza (sec. 12.3),,,,Label: t1/2 about 13 h; Cmax at 8 to 12 h
Dulaglutide,Trulicity,120,,48,24-72,SC,human,A,regulatory_label,FDA label Trulicity (sec. 12.3),,,,"Label: t1/2 about 5 days; Tmax 24 to 72 h at steady state, median 48 h"
Exenatide,Byetta,2.4,,2.1,,SC,human,A,regulatory_label,FDA label Byetta (sec. 12.3),,,,Label: mean terminal t1/2 2.4 h; median Tmax 2.1 h
Tesamorelin,Egrifta,0.13,,0.15,,SC,human,A,regulatory_label,FDA label Egrifta SV (sec. 12.3),,,,Label: mean t1/2 8 min; median Tmax 0.15 h. Older labels and many websites quote 26 to 38 min.
Bremelanotide,PT-141;Vyleesi,2.7,1.9-4.0,1,0.5-1.0,SC,human,A,regulatory_label,FDA label Vyleesi (sec. 12.3),,,,Label: mean terminal t1/2 about 2.7 h (1.9 to 4.0); median Tmax about 1.0 h
Teriparatide,Forteo,1,,0.5,,SC,human,A,regulatory_label,FDA label Forteo (sec. 12.3),,,,Label: serum t1/2 about 1 h; peak about 30 min after SC injection
Setmelanotide,Imcivree,11,,8,,SC,human,A,regulatory_label,FDA label Imcivree (sec. 12.3),,,,Label: effective t1/2 about 11 h; median Tmax 8 h
Octreotide,Sandostatin,1.8,1.7-1.9,0.4,,SC,human,A,regulatory_label,FDA label Sandostatin (sec. 12.3),,,,Label: apparent t1/2 1.7 to 1.9 h; peak 0.4 h after SC injection
Retatrutide,LY3437943,144,,,,SC,human,B,clinical_trial,Urva S et al. Lancet 2022,36354040,,10.1016/S0140-6736(22)02033-5,Phase 1b in type 2 diabetes; abstract: half-life about 6 days
Cagrilintide,,180,159-195,,24-72,SC,human,B,clinical_trial,Enebo LB et al. Lancet 2021,33894838,,10.1016/S0140-6736(21)00845-X,Co-administered with semaglutide 2.4 mg; abstract: t1/2 159 to 195 h; median Tmax 24 to 72 h
CJC-1295 with DAC,DAC:GRF,168,139-194,,,SC,human,B,clinical_trial,Teichman SL et al. J Clin Endocrinol Metab 2006,16352683,,10.1210/jc.2005-1536,Abstract: estimated half-life 5.8 to 8.1 days
Cotadutide,MEDI0382,11,9.5-12.1,,4.5-9.0,SC,human,B,clinical_trial,Ambery PD et al. Br J Clin Pharmacol 2018,29926478,PMC6138475,10.1111/bcp.13688,Abstract: t1/2 9.54 to 12.07 h; Tmax 4.50 to 9.00 h
Thymosin alpha-1,Thymalfasin;Zadaxin,,<3,,1-2,SC,human,B,clinical_trial,Rost KL et al. Int J Clin Pharmacol Ther 1999,10027483,,,Abstract: elimination half-life less than 3 h; Tmax 1 to 2 h; three formulations
Ipamorelin,,2,,,,IV,human,B,clinical_trial,Gobburu JV et al. Pharm Res 1999,10496658,,10.1023/a:1018955126402,Abstract: terminal half-life 2 h. IV infusion only; no SC data
GHRP-6,,2.5,1.4-3.6,,,IV,human,B,clinical_trial,Cabrales A et al. Eur J Pharm Sci 2013,23099431,,10.1016/j.ejps.2012.10.006,"IV bolus, 9 healthy men; abstract: elimination t1/2 2.5 +/- 1.1 h"
Thymosin beta-4,TB-500 (parent protein);NL005,,0.5-2.1,,0.05-0.25,IV,human,B,clinical_trial,Wang X et al. J Cell Mol Med 2021,34346165,PMC8419156,10.1111/jcmm.16693,Full text: t1/2 0.5 to 2.08 h; Tmax 3 to 15 min. Recombinant full-length Tb4. TB-500 (fragment) itself has no human PK.
Hexarelin,,,,,,IV,human,C,clinical_trial,Imbimbo BP et al. Eur J Clin Pharmacol 1994,7957536,,10.1007/BF00191904,"Only the GH response is reported (peak about 30 min, decay t1/2 about 55 min). No drug PK."
BPC-157,PL 14736,,<0.5,,,IM;IV,rat;dog,C,preclinical,He L et al. Front Pharmacol 2022,36588717,PMC9794587,10.3389/fphar.2022.1026182,Abstract: t1/2 less than 30 min in rats and dogs. No human PK published.
Sermorelin,Geref,,,,,,,D,none,,,,,The Geref label was withdrawn and is not on DailyMed. The often quoted 11 to 12 min could not be checked.
Melanotan II,MT-II,,,,,,,D,none,,,,,Dorr 1996 (PMID 8637402) is a phase 1 pilot that reports no PK values.
Semax,,,,,,,,D,none,,,,,Rapid enzymatic degradation reported in rat tissue (PMID 15344653). No human t1/2.
CJC-1295 (no DAC),Mod GRF 1-29,,,,,,,D,none,,,,,No dedicated human PK. Do not use DAC values.
TB-500,Tb4 fragment 17-23,,,,,,,D,none,,,,,See Thymosin beta-4 for the parent protein.
GHK-Cu,Copper tripeptide-1,,,,,,,D,none,,,,,
KPV,,,,,,,,D,none,,,,,
Selank,,,,,,,,D,none,,,,,Preclinical only.
DSIP,,,,,,,,D,none,,,,,
AOD-9604,,,,,,,,D,none,,,,,Animal only.
LL-37,,,,,,,,D,none,,,,,Murine data only; no systemic human PK.
Epitalon,Epithalon,,,,,,,D,none,,,,,No published PK in any species found.
GHRP-2,Pralmorelin,,,,,,,D,none,,,,,
IGF-1 LR3,,,,,,,,D,none,,,,,The widely quoted 20-30 h value has no primary source we could find.
MOTS-c,,,,,,,,D,none,,,,,